aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2020 Financial Results
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged
in the discovery and development of innovative medicines based on
novel immunological pathways, today announced that it will report
second quarter 2020 financial results and provide a corporate
update after the market close on Thursday, August 13, 2020.
Conference Call and Webcast
Details:Thursday, August 13th @ 5:00 p.m. EDT / 2:00 p.m.
209-905-5951Conference ID: 5176802Webcast:
aTyr is a biotherapeutics company engaged in the
discovery and development of innovative medicines based on novel
immunological pathways. aTyr’s research and development efforts are
concentrated on a newly discovered area of biology, the
extracellular functionality and signaling pathways of tRNA
synthetases. aTyr has built a global intellectual property estate
directed to a potential pipeline of protein compositions derived
from 20 tRNA synthetase genes and their extracellular targets.
aTyr’s primary focus is ATYR1923, a clinical-stage product
candidate which binds to the neuropilin-2 receptor and is designed
to down-regulate immune engagement in inflammatory lung diseases.
For more information, please visit
|Investor Relations, aTyr